文献速递临床微生物分子诊断

亚胺培南/瑞来巴坦联合MALDI-TOF MS快速预测铜绿假单胞菌碳青霉烯酶

Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS.
PubMed 文献 · J Clin Microbiol · 2025-03-25

该研究开发了一种基于MALDI-TOF MS的快速方法,通过检测亚胺培南在有无瑞来巴坦存在下的水解,预测铜绿假单胞菌中碳青霉烯酶的存在。方法在419株分离株(包括重组株和全基因组测序表征的临床株)中开发,并在250株前瞻性收集的临床分离株中验证,结果显示表型与MALDI-TOF MS水解结果的一致率为98%(246/250),与β-内酰胺耐药基因型的一致率为100%。所有结果在1小时内获得,该方法有望用于常规实验室筛查,以支持亚胺培南/瑞来巴坦的合理使用。

要点

  • MALDI-TOF MS法可在1小时内预测铜绿假单胞菌碳青霉烯酶(GES酶除外)。
  • 前瞻性验证中表型与水解结果一致率98%(246/250),与基因型一致率100%。
  • 对GES产生菌及某些突变耐药机制(MIC 4–8 mg/L)检测存在误差。

核心结论

  • 基于MALDI-TOF MS的亚胺培南/瑞来巴坦水解法可快速、准确地预测铜绿假单胞菌碳青霉烯酶(GES酶除外),并辅助预测亚胺培南/瑞来巴坦敏感性。

研究设计与样本

  • 方法开发使用419株铜绿假单胞菌分离株(包括重组株和WGS表征的临床株),涵盖最重要β-内酰胺耐药机制。
  • 方法先对回顾性收集株评估,再对250株前瞻性收集的临床分离株验证。

主要发现

  • 前瞻性验证中,表型与MALDI-TOF MS水解结果一致率为98%(246/250)。
  • 与β-内酰胺耐药基因型的一致率为100%。
  • 观察到检测GES产生菌及与亚胺培南/瑞来巴坦耐药相关的不同突变耐药机制(MIC 4–8 mg/L)时存在误差。
  • 所有结果在1小时内获得。

关键数值与推荐

  • 表型与MALDI-TOF MS水解结果一致率98%(246/250)。
  • 与β-内酰胺耐药基因型一致率100%。
  • 检测误差涉及GES产生菌和MIC 4–8 mg/L的突变耐药机制。

临床怎么用

  • 该方法可作为快速、易操作的检测手段,用于铜绿假单胞菌碳青霉烯酶(GES酶除外)的检测。
  • 在常规实验室筛查中实施该方法可促进亚胺培南/瑞来巴坦用于治疗铜绿假单胞菌感染的正确使用。

局限性

  • 检测GES产生菌时存在误差。
  • 检测与亚胺培南/瑞来巴坦耐药相关的不同突变耐药机制(MIC 4–8 mg/L)时存在误差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pseudomonas aeruginosa is a major nosocomial pathogen commonly involved in multidrug-resistant (MDR) infections that are very difficult to treat. Imipenem/relebactam is a new carbapenem/β-lactamase inhibitor combination with robust activity against P. aeruginosa. However, resistance is increasingly reported, and rapid detection is, therefore, crucial so that appropriate treatments can be prescribed. We have developed a rapid MALDI TOF-MS-based method that can accurately predict the presence of carbapenemases in P. aeruginosa using imipenem/relebactam. The method was developed using a retrospective and a prospective collection of 419 P. aeruginosa isolates (including recombinant isolates and WGS-characterized clinical strains) encompassing the most important β-lactam resistance mechanisms. The MALDI TOF-MS method is based on the detection of the hydrolysis of imipenem in the presence or absence of relebactam, measuring modifications in the mass spectra of imipenem after incubation with bacteria. The method was evaluated against a retrospective collection and then validated against 250 prospectively collected clinical isolates, showing a 98% (246/250) agreement between the phenotype and the MALDI-TOF MS hydrolysis result and a 100% accordance with the β-lactam resistance genotype. Some errors in detecting GES-producing isolates and in detecting different mutational resistance mechanisms associated with imipenem/relebactam resistance (MICs ranging from 4 to 8 mg/L) were observed. All results were obtained within 1 hour, positioning the MALDI-TOF-based test as a rapid and easy-to-perform method for detection of carbapenemases (except GES enzymes) in P. aeruginosa. Besides, implementation of the method in routine laboratory screening would facilitate the correct use of imipenem/relebactam to treat P. aeruginosa infections.IMPORTANCEWhile several rapid diagnostic methods have been developed for the detection of ESBLs and carbapenemases to improve treatment decision-making in Enterobacterales, there is a lack of approaches to rapidly identify resistance mechanisms and predict β-lactam susceptibility in Pseudomonas aeruginosa. Taking advantage of the mechanism of action and the high efficacy of the newly developed β-lactam/β-lactamase inhibitor combination imipenem/relebactam against P. aeruginosa, we developed a WGS-guided, MALDI-TOF-based algorithm that accurately predicts the presence of carbapenemase enzymes in this bacterium and aids in forecasting the imipenem/relebactam susceptibility profile. The implementation of this method in routine laboratory testing would provide significant support in the rapid decision-making for the use of imipenem/relebactam in severe P. aeruginosa infections.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Candela A, Fernández-Billón M, Aja-Macaya P, et al. Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS. J Clin Microbiol. 2025. PMID: 40130831. doi:10.1128/jcm.01105-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。